

4 April 2023

Treatment of Breast Cancer

I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of Dec 2022 and the end of Feb 2023.

1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the latest three months for which you have data (ideally between Dec 2022 and Feb 2023)?

Name of Medicine	Number of Patients Treated
1.1 Abemaciclib (Verzenios)	11
1.2 Alpelisib (Piqray)	<5
1.3 Anastrozole (anastrozole or Arimidex)	<5
1.4 Exemestane (exemestane or Aromasin)	<5
1.5 Fulvestrant (fulvestrant or Faslodex)	11
1.6 Letrozole (letrozole or Femara)	<5
1.7 Palbociclib (Ibrance)	38
1.8 Ribociclib (Kisqali)	18

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. How many patients received Abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the latest three months for which you have data (ideally between Dec 2022 and Feb 2023)?

If you do not have data on early breast cancer, please state how many patients received Abemaciclib (Verzenios) as adjuvant treatment?

Number of Patients Treated
11 (early stage not recorded)

4 April 2023

3. How many patients received Abemaciclib in combination with an aromatase inhibitor (anastrozole or exemestane or letrozole) for early breast cancer and locally advanced or metastatic breast cancer in the latest three months for which you have data (ideally between Dec 2022 and Feb 2023)?

The TNM values associated with each stage of breast cancer are included for reference only.

Name of Combination	Breast Cancer Staging	TNM (for reference only) Source: Cancer Research UK	Number of Patients Treated
3.1 Abemaciclib + aromatase inhibitor (anastrozole or exemestane or letrozole)	Early breast cancer	<i>T1N0M0 or T0N1M0 or T1N1M0 or T2N1M0 or T3N0M0</i>	<5
3.2 Abemaciclib + aromatase inhibitor (anastrozole or exemestane or letrozole)	Locally advanced or metastatic breast cancer	<i>T0N2M0 or T1N2M0 or T2N2M0 or T3N1M0 or T3N2M0 or T4N0M0 or T4N1M0 or T4N2M0 or T*N3M0 or T*N*M1</i>	<5

As per Question 1, we are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act.

4. How many patients received Olaparib (Lynparza) as adjuvant treatment for early breast cancer in the latest three months for which you have data (ideally between Dec 2022 and Feb 2023)?

If you do not have data on early breast cancer, please state how many patients received Olaparib (Lynparza) as adjuvant treatment?

Number of Patients Treated
<5 (early stage not recorded)

Again, we are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act.

4 April 2023

5. How many patients were treated with the following medicines in combination in the latest three months for which you have data (ideally between Dec 2022 and Feb 2023)?

Name of Combination	Number of Patients Treated
5.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	5
5.2 Abemaciclib (Verzenios) + Anastrozole (anastrozole or Arimidex)	<5
5.3 Abemaciclib (Verzenios) + Exemestane (exemestane or Aromasin)	<5
5.4 Abemaciclib (Verzenios) + Letrozole (letrozole or Femara)	<5
5.7 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)	<5
5.8 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	<5
5.9 Palbociclib (Ibrance) + Anastrozole (anastrozole or Arimidex)	<5
5.10 Palbociclib (Ibrance) + Exemestane (exemestane or Aromasin)	<5
5.11 Palbociclib (Ibrance) + Letrozole (letrozole or Femara)	<5
5.12 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	<5
5.13 Ribociclib (Kisqali) + Anastrozole (anastrozole or Arimidex)	<5
5.14 Ribociclib (Kisqali) + Exemestane (exemestane or Aromasin)	<5
5.15 Ribociclib (Kisqali) + Letrozole (letrozole or Femara)	<5

We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act.

4 April 2023

6. How many patients were treated with Olaparib (Lynparza) as monotherapy for locally advanced or metastatic breast cancer in the latest three months for which you have data (ideally between Dec 2022 and Feb 2023)?

Number of Patients Treated
<5 (stage not recorded)

Again, we are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act.

7. Which of these protocols does your Trust follow when issuing prescriptions for aromatase inhibitors (anastrozole or exemestane or letrozole) prescribed in combination with CDK4/6 inhibitors (abemaciclib or palbociclib or ribociclib)?

Name of combination	Yes or no
7.1 Aromatase inhibitors and CDK4/6 inhibitors are issued together To Take Out at the hospital	No
7.2 Aromatase inhibitors and CDK4/6 inhibitors are issued separately . The CDK4/6 inhibitors (abemaciclib or palbociclib or ribociclib) are issued To Take Out at the hospital. The aromatase inhibitors (anastrozole or exemestane or letrozole) are issued as an FP10 to the patient or a request is sent to the GP to issue in the community	Yes
7.3 Both protocols above	No